This company seems to have been delisted
Reason: Filed for bankruptcy
Last recorded trade on: June 22, 2023
Source: https://www.bloomberg.com/news/articles/2023-05-03/generic-drugmaker-lannett-files-for-chapter-11-bankruptcy
Reason: Filed for bankruptcy
Last recorded trade on: June 22, 2023
Source: https://www.bloomberg.com/news/articles/2023-05-03/generic-drugmaker-lannett-files-for-chapter-11-bankruptcy
Lannett Company
LCI
S$0.87
Share price
0.00%
Change (1 day)
-71.76%
Change (1 year)
Categories
Lannett Company (LCI) - Total assets
Total assets on the balance sheet as of March 2023 : S$0.42 Billion
According to Lannett Company's latest financial reports the company's total assets are S$0.42 Billion. A company’s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.
Lannett Company - Total assets on balance sheet (from 2001 to 2023)
Total assets by year
| Year | Total assets | Change |
|---|---|---|
| 2022-06-30 | S$0.67 B | -26.75% |
| 2021-06-30 | S$0.91 B | -41.95% |
| 2020-06-30 | S$1.58 B | -1.32% |
| 2019-06-30 | S$1.60 B | -25.24% |
| 2018-06-30 | S$2.14 B | -2.73% |
| 2017-06-30 | S$2.20 B | -7.12% |
| 2016-06-30 | S$2.37 B | 246.66% |
| 2015-06-30 | S$0.68 B | 60.41% |
| 2014-06-30 | S$0.42 B | 100.74% |
| 2013-06-30 | S$0.21 B | 6.19% |
| 2012-06-30 | S$0.20 B | 10.57% |
| 2011-06-30 | S$0.18 B | -6.71% |
| 2010-06-30 | S$0.19 B | 8% |
| 2009-06-30 | S$0.17 B | 13.16% |
| 2008-06-30 | S$0.15 B | -0.94% |
| 2007-06-30 | S$0.16 B | -4.84% |
| 2006-06-30 | S$0.16 B | 4.97% |
| 2005-06-30 | S$0.16 B | -23.79% |
| 2004-06-30 | S$0.21 B | 313.27% |
| 2003-06-30 | S$51.02 M | 72.79% |
| 2002-06-30 | S$29.53 M | 3.43% |
| 2001-06-30 | S$28.55 M |
Total Assets for similar companies or competitors
| Company | Total assets | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | S$264.98 B | 62,067.69% | 🇺🇸 USA |
 Johnson & Johnson JNJ | S$246.69 B | 57,777.20% | 🇺🇸 USA |
 Abbott Laboratories ABT | S$103.74 B | 24,240.15% | 🇺🇸 USA |
 Novartis NVS | S$127.30 B | 29,766.66% | 🇨🇭 Switzerland |
 GlaxoSmithKline GSK | S$99.91 B | 23,340.13% | 🇬🇧 UK |